熱門資訊> 正文
Candel Therapeutics GAAP每股收益为-0.28美元
2024-05-15 02:35
- Candel Therapeutics press release (NASDAQ:CADL): Q1 GAAP EPS of -$0.28.
- Cash and cash equivalents, as of March 31, 2024, were $25.7 million, as compared to $35.4 million as of December 31, 2023. Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the fourth quarter of 2024.
More on Candel Therapeutics
- Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
- Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment
- Candel stock soars on positive data from mid-stage pancreatic cancer drug trial
- Seeking Alpha’s Quant Rating on Candel Therapeutics
- Historical earnings data for Candel Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
